495 related articles for article (PubMed ID: 26729008)
1. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
[TBL] [Abstract][Full Text] [Related]
2. Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.
Hodgkin D; Horgan CM; Quinn AE; Merrick EL; Stewart MT; Leslie LK
Clin Ther; 2014 Dec; 36(12):2034-2046. PubMed ID: 25450473
[TBL] [Abstract][Full Text] [Related]
3. Management of access to branded psychotropic medications in private health plans.
Hodgkin D; Horgan CM; Garnick DW; Len Merrick E; Volpe-Vartanian J
Clin Ther; 2007 Feb; 29(2):371-80. PubMed ID: 17472830
[TBL] [Abstract][Full Text] [Related]
4. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
Robinson SW; Brantley K; Liow C; Teagarden JR
J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
[TBL] [Abstract][Full Text] [Related]
5. The effect of a three-tier formulary on antidepressant utilization and expenditures.
Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
[TBL] [Abstract][Full Text] [Related]
6. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
7. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
8. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
[TBL] [Abstract][Full Text] [Related]
9. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
10. Availability of addiction medications in private health plans.
Horgan CM; Reif S; Hodgkin D; Garnick DW; Merrick EL
J Subst Abuse Treat; 2008 Mar; 34(2):147-56. PubMed ID: 17499959
[TBL] [Abstract][Full Text] [Related]
11. The relationship of antidepressant prescribing concentration to treatment duration and cost.
Hodgkin D; Merrick EL; Hiatt D
J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
[TBL] [Abstract][Full Text] [Related]
12. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
13. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
14. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
[TBL] [Abstract][Full Text] [Related]
15. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
16. Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans.
Ben-Joseph R; Chen CC; De AP; Wade RL; Shah D
J Med Econ; 2014 Oct; 17(10):708-18. PubMed ID: 24888403
[TBL] [Abstract][Full Text] [Related]
17. Insurance coverage and the treatment of mental illness: effect on medication and provider use.
Mulvale G; Hurley J
J Ment Health Policy Econ; 2008 Dec; 11(4):177-99. PubMed ID: 19096092
[TBL] [Abstract][Full Text] [Related]
18. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan.
Nau DP; Chi C; Mallya U; Kirking DM
J Manag Care Pharm; 2007 Mar; 13(2):135-41. PubMed ID: 17330974
[TBL] [Abstract][Full Text] [Related]
19. Trends in mental health insurance benefits and out-of-pocket spending.
McKusick DR; Mark TL; King EC; Coffey RM; Genuardi J
J Ment Health Policy Econ; 2002 Jun; 5(2):71-8. PubMed ID: 12529560
[TBL] [Abstract][Full Text] [Related]
20. What Determines How Much Your Patient Pays for Their Medication in the United States?
Novack GD
Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
